Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07187531 | SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | PHASE2 | RECRUITING | 159 | — | — | Nov 25, 2025 | Dec 1, 2028 | May 29, 2026 | 71 | United States, Australia +13 |
This is a measure of endogenous insulin production and β cell function (change from baseline in C-peptide ln \[AUC+1\] at 12 months)
| Arm | Type | Description |
|---|---|---|
| High Dose SAB-142 | EXPERIMENTAL | Part A: Open-label, parallel arm study. Part B: Double-blind, placebo-controlled, parallel-arm study. Enrolment into Part B may commence once all participants in Part A have been randomised. |
| Low Dose SAB-142 | EXPERIMENTAL | Part A: Open-label, parallel arm study. Part B: Double-blind, placebo-controlled, parallel-arm study. Enrolment into Part B may commence once all participants in Part A have been randomised. |
| Placebo | PLACEBO_COMPARATOR | Part B: This is a double-blind, placebo-controlled, parallel-arm study. Enrolment into Part B may commence once all participants in Part A have been randomised. |
| Name | Type | Description |
|---|---|---|
| High Dose SAB-142 | DRUG | High Dose SAB-142 |
| Low Dose SAB-142 | DRUG | Low Dose SAB-142 |
| Placebo | OTHER | Placebo |
Inclusion Criteria: 1. Participant and/or appropriate legal guardian must have given written informed consent and/or assent according to local, regional and/or country specific guidance before any study-related activities are carried out and must be able to understand the full nature and purpose of...